Orlistat

Active ingredient: Orlistat

In short: ORLISTAT is indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in: adults and pediatric patients aged 12 years and older with obesity. adults with overweight in the presence of at least one weight-

Forms & strengthsCapsules: 120 mg, turquoise, imprinted with ā€œXENICAL 120ā€ in black ink.
LabelH2-Pharma LLC
Label updatedNov 05, 2026

What is Orlistat used for?

ORLISTAT is indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in:

adults and pediatric patients aged 12 years and older with obesity.

adults with overweight in the presence of at least one weight-related comorbid condition.

Orlistat dosage

The recommended dosage of ORLISTAT is one 120 mg capsule taken orally three times a day with each main meal containing fat (during or up to 1 hour after the meal). Dosages above 120 mg three times a day have not been shown to provide additional benefit.

Take ORLISTAT with a nutritionally balanced, reduced-calorie diet that contains approximately 30% of calories from fat .

Distribute the daily intake of fat, carbohydrate, and protein over three main meals.

Skip the dose of ORLISTAT if a meal is missed or contains no fat. Resume ORLISTAT at the next scheduled main meal containing fat.

Administer a multivitamin containing fat-soluble vitamins once daily at least 2 hours before or 2 hours after administration of ORLISTAT, or at bedtime .

How to take Orlistat — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Loss of Effect of Certain Medications and Dietary Supplements with Coadministration of ORLISTAT

Advise patients taking cyclosporine, levothyroxine, warfarin, amiodarone, antiepileptic drugs, antiretroviral drugs, certain fat-soluble vitamins, and beta carotene that ORLISTAT may reduce their effectiveness .

Liver Injury

Inform patients of the risk of liver injury and educate patients on the signs and symptoms of hepatic dysfunction (anorexia, pruritus, jaundice, dark urine, light-colored stools, or right upper quadrant pain). Instruct patients to contact their health care provider if they experience signs or symptoms of hepatic dysfunction .

Oxalate Nephrolithiasis and Oxalate Nephropathy with Renal Failure

Inform patients of the potential risk for oxalate nephrolithiasis and oxalate nephropathy and explain the associated signs and symptoms, including of renal failure. Instruct patients to contact their health care provider if they experience signs or symptoms of oxalate nephrolithiasis or oxalate nephropathy .

Acute Gallbladder Disease

Inform patients of the risk of acute gallbladder disease. …

Warnings & precautions

Do not take this medicine if: ORLISTAT is contraindicated in patients with:

chronic malabsorption syndrome

cholestasis

known hypersensitivity to orlistat or any of the inactive ingredients in ORLISTAT. Serious hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported with ORLISTAT .

Serious outcomes due to the loss of effect of cyclosporine, levothyroxine, warfarin, amiodarone, antiepileptic drugs, antiretroviral drugs, certain fat-soluble vitamins, and beta carotene have been reported with coadministration of ORLISTAT. Do not coadminister ORLISTAT simultaneously with cyclosporine or levothyroxine . Administer cyclosporine 3 hours after the administration of ORLISTAT. Administer levothyroxine and ORLISTAT at least 4 hours apart. Administer a multivitamin supplement at least 2 hours before or 2 hours after the administration of ORLISTAT, or at bedtime. Monitor the effectiveness of cyclosporine, levothyroxine, warfarin, amiodarone, antiepileptic drugs, antiretroviral drugs, certain fat-soluble vitamins, and beta carotene, as clinically indicated .

There have been rare postmarketing reports of severe liver injury with hepatocellular necrosis or acute hepatic failure in patients treated with ORLISTAT, with some of these cases resulting in liver transplant or death . Instruct patients to report any symptoms of hepatic dysfunction (anorexia, pruritus, jaundice, dark urine, light-colored stools, or right upper quadrant pain) while taking ORLISTAT. When these symptoms occur, immediately discontinue ORLISTAT and other suspected medications and obtain liver function tests, including ALT and AST levels.

ORLISTAT may increase levels of urinary oxalate. Cases of oxalate nephrolithiasis and oxalate nephropathy with renal failure have been reported . …

Orlistat side effects

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in patients.

Most Commonly Observed Adverse Reactions during 1 Year of Treatment

ORLISTAT was evaluated for safety in adults with obesity or overweight with at least one comorbid condition in seven multicenter, double-blind, placebo-controlled clinical trials of 1- to 2-years duration, and in a 4-year trial. The seven trials included 1,466 patients treated with placebo, 1,913 patients treated with ORLISTAT 120 mg orally three times a day, and 809 patients treated with unapproved dosages of ORLISTAT. Age of the patients ranged from 17 to 78 years; 80% were female, 91% White, 6% Black or African American, 2% were of Hispanic or Latino ethnicity, and 1% of other races. Six of the trials enrolled patients without type 2 diabetes mellitus (Trials 1-6) and one of the trials enrolled a population of patients with type 2 diabetes mellitus (Trial 7). The 4-year trial (Trial 8) included 3,304 patients, age range 30-58 years; 55% were female; 99% were White and 1% other races. This trial included a subset of patients with abnormal glucose at baseline

.

In placebo-controlled clinical trials, 9% of patients treated with ORLISTAT discontinued treatment due to adverse reactions, compared with 5% of placebo-treated patients. …

Drug interactions

Table 4 describes the clinically significant drug and dietary supplement interactions with ORLISTAT.

Table

4

Clinically Significant Drug and Dietary Supplement Interactions with ORLISTAT

Cyclosporine

Clinical Impact | Coadministration of ORLISTAT and cyclosporine reduces cyclosporine plasma levels .

Intervention | Avoid simultaneous coadministration of ORLISTAT and cyclosporine. Administer cyclosporine 3 hours after the administration of ORLISTAT. In those patients whose cyclosporine levels are being measured, monitor more frequently .

Fat-soluble

Vitamin Supplements and Analogues

Clinical Impact | The absorption of beta-carotene supplements is reduced when concomitantly administered with ORLISTAT. ORLISTAT also inhibited absorption of a vitamin E acetate supplement. The effect of ORLISTAT on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K is not known .

Intervention | Administer a multivitamin supplement at least 2 hours before or 2 hours after the administration of ORLISTAT, or at bedtime .

Levothyroxine

Clinical Impact | Hypothyroidism has been reported in patients treated concomitantly with ORLISTAT and levothyroxine postmarketing.

Intervention | Avoid simultaneous coadministration of ORLISTAT and levothyroxine. …

About this medicine

ORLISTAT is an intestinal lipase inhibitor.

Orlistat is (S)-2-formylamino-4-methyl-pentanoic acid (S)-1-[[(2S, 3S)-3-hexyl-4-oxo-2-oxetanyl] methyl]-dodecyl ester. Its empirical formula is C29H53NO5, and its molecular weight is 495.7. It is a single diastereomeric molecule that contains four chiral centers, with a negative optical rotation in ethanol at 529 nm. The structure is:

Orlistat is a white to off-white crystalline powder. Orlistat is practically insoluble in water, freely soluble in chloroform, and very soluble in methanol and ethanol. Orlistat has no pK

a within the physiological pH range.

Each ORLISTAT capsule contains a pellet formulation consisting of 120 mg of the active ingredient, orlistat, as well as the inactive ingredients microcrystalline cellulose, povidone, sodium lauryl sulfate, sodium starch glycolate, and talc. The capsule shell contains FD&C Blue No. 2 (with black printing ink containing black iron oxide, pharmaceutical grade shellac, potassium hydroxide, propylene glycol, and strong ammonium solution), gelatin, and titanium dioxide. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID f81dfaeb-46d5-47ce-9ef6-19259f5ac61c. Read the full official label on DailyMed.

Related medicines

Tirzepatide Methylphenidate Lisdexamfetamine Amphetamine Serdexmethylphenidate and Dexmethylphenidate Benzphetamine Phendimetrazine Centanafadine